Abstract:Macrocyclic peptides are predominantly peptide structures bearing one or more rings and spanning multiple amino acid residues. Macrocyclization has become a common approach for improving the pharmacological properties and bioactivity of peptides. A variety of ribosomal-derived and non-ribosomal synthesized cyclization approaches have been established. The biosynthesis of backbone macrocyclic peptides using seven new emerging methodologies will be discussed with regard to the features and strengths of each platform rather than medicinal chemistry tools. The mRNA display variant, known as the random nonstandard peptide integrated discovery (RaPID) platform, utilizes flexible in vitro translation (FIT) to access macrocyclic peptides containing nonproteinogenic amino acids (NAAs). As a new discovery approach, the ribosomally synthesized and post-translationally modified peptides (RiPPs) method involves the combination of ribosomal synthesis and the phage screening platform together with macrocyclization chemistries to generate libraries of macrocyclic peptides. Meanwhile, the split-intein circular ligation of peptides and proteins (SICLOPPS) approach relies on the in vivo production of macrocyclic peptides. In vitro and in vivo peptide library screening is discussed as an advanced strategy for cyclic peptide selection. Specifically, biosynthetic bicyclic peptides are highlighted as versatile and attractive modalities. Bicyclic peptides represent another type of promising therapeutics that allow for building blocks with a heterotrimeric conjugate to address intractable challenges and enable multimer complexes via linkers. Additionally, we discuss the cell-free chemoenzymatic synthesis of macrocyclic peptides with a non-ribosomal catalase known as the non-ribosomal synthetase (NRPS) and chemo-enzymatic approach, with recombinant thioesterase (TE) domains. Novel insights into the use of peptide library tools, activity-based two-hybrid screening, structure diversification, inclusion of NAAs, combinatorial libraries, expanding the toolbox for macrocyclic peptides, bicyclic peptides, chemoenzymatic strategies, and future perspectives are presented. This review highlights the broad spectrum of strategy classes, novel platforms, structure diversity, chemical space, and functionalities of macrocyclic peptides enabled by emerging biosynthetic platforms to achieve bioactivity and for therapeutic purposes.

Autophagy Inducing Cyclic Peptides Constructed by Methionine Alkylation

Inhibition of Autophagy by a Small Molecule Through Covalent Modification of the LC3 Protein

Computational Design of Novel Cyclic Peptides Endowed with Autophagy-Inhibiting Activity on Cancer Cell Lines

Reversible stapling of unprotected peptides via chemoselective methionine bis-alkylation/dealkylation.

Constructing Cyclic Peptides Using an On-Tether Sulfonium Center

Efficient Delivery of Cyclic Peptides into Mammalian Cells with Short Sequence Motifs

Peptide modified, programmable DNA tetrahedra to modulate autophagy in biological systems

Macrocyclic Peptide Construction Through C-H Activation Strategy.

A Sulfonium Tethered Peptide Ligand Rapidly and Selectively Modifies Protein Cysteine in Vicinity

Exploration of Novel Macrocyclic Dipeptide N-benzyl Amides As Proteasome Inhibitors.

Macrocyclization of an all-d linear α-helical peptide imparts cellular permeability

A novel method for the synthesis of macrocyclic peptides using arylsulfonyloxyacetic acids as N -terminus functional groups

Peptide Macrocyclization Through Palladium-Catalyzed Late-Stage C-H Activation.

A manganese (II)-based coordinative dendrimer with robust efficiency in intracellular peptide delivery

Macrocyclization of Bioactive Peptides with Internal Thiazole Motifs Via Palladium-Catalyzed C–H Olefination

Intramolecular Methionine Alkylation Constructs Sulfonium Tethered Peptides for Protein Conjugation

Biosynthetic Strategies for Macrocyclic Peptides

Modular synthesis of clickable peptides via late-stage maleimidation on C(7)-H tryptophan

Development of Macrocyclic Peptides Containing Epoxyketone with Oral Availability as Proteasome Inhibitors.

Biocompatible Strategies for Peptide Macrocyclisation

Landscaping macrocyclic peptides: stapling hDM2-binding peptides for helicity, protein affinity, proteolytic stability and cell uptake